Evidence map›Paper›PMID 42064490›Full record

ArticleCureus2026

Hydralazine-Induced Antineutrophil Cytoplasmic Antibody Vasculitis Causing Gastroduodenal Artery Perforation.

Katherine N Gonzalez, Daniel Faradji, Kyle Schneider, Shivani Desai, Huda N Khan, Jaimin Patel

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katherine N GonzalezInternal Medicine, Methodist Health System, Dallas, USA.
Daniel FaradjiInternal Medicine, Methodist Health System, Dallas, USA.
Kyle SchneiderInternal Medicine, Methodist Dallas Medical Center, Dallas, USA.
Shivani DesaiInternal Medicine, Methodist Health System, Dallas, USA.
Huda N KhanInternal Medicine, Methodist Health System, Dallas, USA.
Jaimin PatelInternal Medicine, Methodist Dallas Medical Center, Dallas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides are rare disorders characterized by inflammation of small blood vessels, including capillaries, venules, and arterioles. The three main subtypes of primary ANCA-associated vasculitides (i.e., granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis) can present with diverse and nonspecific symptoms, making diagnosis difficult. We report the case of secondary, drug-induced ANCA vasculitis in a female patient who presented with hemoptysis and dyspnea complicated by acute kidney injury and severe anemia. Serologic testing and renal biopsy confirmed the diagnosis of ANCA-associated vasculitis (AAV). Her hospital course was complicated by multiple gastrointestinal bleeds requiring two interventional radiology procedures, first on her gastroduodenal artery and later on her inferior pancreaticoduodenal artery. The patient was treated with cyclophosphamide and plasma exchange during hospitalization and was transitioned to rituximab and intravenous steroids, resulting in an eventual recovery. This case highlights the intricacies of diagnosing AAV and the potential severe, life-threatening complications, such as gastrointestinal hemorrhage. Early recognition and a multidisciplinary approach are critical to evaluate and treat as well as to improve outcomes in patients with this rare but serious condition.

Indexed as

anca-vasculitisgastroduodenal artery perforationgastrointestinal hemorrhagehemoptysishydralazine

Identifiers

PMID42064490
PMCPMC13128252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.